Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | UGT8 | Q16880 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22354451 | 1.00 | ALDH1A1 (0.49) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL25161958 | 0.94 | ALDH1A1 (0.47) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL26261918 | 0.94 | ALDH1A1 (0.47) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL25162163 | 0.94 | ALDH1A1 (0.45) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL13669538 | 0.92 | ALDH1A1 (0.44) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL14422380 | 0.92 | ALDH1A1 (0.44) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL12091395 | 0.92 | ALDH1A1 (0.44) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL12091394 | 0.92 | ALDH1A1 (0.44) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL4086161 | 0.91 | ALDH1A1 (0.54) | ALDH1A1POLBCYP3A4CYP2D6PKM | |
| SCHEMBL25162116 | 0.91 | KDM4E (0.44) | ALDH1A1POLBHSD17B10CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230346971-A1 | METHOD FOR TREATING TUMOURS BY CAPTURING COPPER AND/OR IRON | LYON INGENIERIE PROJETS (FR) | 2023-11-02 | — | — | US | disclosed |
| US-20230295227-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | ANTAROS TRACER AB (SE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295227-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | ANTAROS TRACER AB (SE) | 2023-09-21 | — | — | US | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230218781-A1 | METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION | LYON INGENIERIE PROJETS (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230147035-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY | 2023-05-11 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2023-04-27 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
| US-7226577-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING, S. P. A. (IT) | 2007-06-05 | — | — | US | disclosed |
| US-7226577-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING, S. P. A. (IT) | 2007-06-05 | — | — | US | disclosed |
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ALDH1A1 3098/4885POLB 4507/4885HSD17B10 3201/4885 |
| US-20230346971-A1 | METHOD FOR TREATING TUMOURS BY CAPTURING COPPER AND/OR IRON | SLC40A1, FECH, TFRC | ALDH1A1 1086/4885POLB 2491/4885HSD17B10 2920/4885 |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FRS2, PAICS, FGF23 | ALDH1A1 3761/4885POLB 3568/4885HSD17B10 3829/4885 |
| US-20230295227-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | COL1A1, INHA, COL2A1 | ALDH1A1 1860/4885POLB 258/4885HSD17B10 2286/4885 |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | GIPR, GRPR, GLP1R | ALDH1A1 4537/4885POLB 4678/4885HSD17B10 4682/4885 |
| US-20230147035-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | KLK3, FOLH1, ASGR1 | ALDH1A1 3647/4885POLB 4000/4885HSD17B10 2704/4885 |
| US-20230218781-A1 | METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION | CD14, CD209, MSR1 | ALDH1A1 3219/4885POLB 4615/4885HSD17B10 4819/4885 |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | ALDH1A1 4079/4885POLB 1557/4885HSD17B10 4378/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | ALDH1A1 4127/4885POLB 471/4885HSD17B10 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.